Compare Amgen, Inc. (AMGN) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Oxford Lane Capital Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Oxford Lane Capital Corp trades at $9.21 (market cap $891.54M). The key difference: Amgen, Inc. is far larger — about 220× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (26.29%). Which is the better fit depends on your goals.
| AMGN | OXLC | |
|---|---|---|
Market Cap | $196.12B | $891.54M |
Sector | Health | Financials |
52-Week High | $388.16 | $20.80 |
52-Week Low | $271.18 | $8.15 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 26.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
OXLC trades at $9.13, up 0.66% today, with a mixed technical outlook showing bullish moving averages but overbought RSI readings. The company reported a net income margin exceeding 100% for 2025, yet recent quarterly earnings have consistently missed expectations, including a significant loss in Q1 2026. Dividend payments remain active, but negative ROE and ROA highlight financial strain. Analyst sentiment is divided, with a 50% buy rating amid concerns over net asset value declines and high distribution yields.
The outlook for OXLC is clouded by severe profitability challenges and volatile earnings, presenting high risk. While the dividend yield attracts income seekers, sustained NAV erosion and operational cash outflows signal underlying weakness. Investment opportunity hinges on a turnaround in CLO equity markets, but current fundamentals suggest caution is warranted for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
